Par Drugs And Chemicals Limited (PAR) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.076x

Based on the latest financial reports, Par Drugs And Chemicals Limited (PAR) has a cash flow conversion efficiency ratio of 0.076x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs80.95 Million ≈ $875.41K USD) by net assets (Rs1.06 Billion ≈ $11.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Par Drugs And Chemicals Limited (PAR) market capitalisation for the company's overall valuation and market capitalisation.

Par Drugs And Chemicals Limited - Cash Flow Conversion Efficiency Trend (2016–2026)

This chart illustrates how Par Drugs And Chemicals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Par Drugs And Chemicals Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Par Drugs And Chemicals Limited ranked by their cash flow conversion efficiency. Explore PAR cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Knightscope Inc
NASDAQ:KSCP
-0.382x
Seker Finansal Kiralama AS
IS:SEKFK
0.184x
Kodi-S Co Ltd
KQ:080530
-0.029x
Volitionrx Ltd
NYSE MKT:VNRX
0.154x
Salee Colour Public Company Limited
BK:COLOR
0.066x
YOC AG
F:YOC
0.206x
Lleidanetworks Serveis Telematics SA
MC:LLN
0.270x
Telefast Indonesia 
JK:TFAS
0.023x

Annual Cash Flow Conversion Efficiency for Par Drugs And Chemicals Limited (2016–2026)

The table below shows the annual cash flow conversion efficiency of Par Drugs And Chemicals Limited from 2016 to 2026. View Par Drugs And Chemicals Limited (PAR) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2026-03-31 Rs1.12 Billion
≈ $12.11 Million
Rs164.32 Million
≈ $1.78 Million
0.147x -10.13%
2025-03-31 Rs989.75 Million
≈ $10.70 Million
Rs161.60 Million
≈ $1.75 Million
0.163x -30.95%
2024-03-31 Rs856.32 Million
≈ $9.26 Million
Rs202.49 Million
≈ $2.19 Million
0.236x +25.93%
2023-03-31 Rs712.38 Million
≈ $7.70 Million
Rs133.77 Million
≈ $1.45 Million
0.188x +47.65%
2022-03-31 Rs598.77 Million
≈ $6.48 Million
Rs76.15 Million
≈ $823.55K
0.127x -45.05%
2021-03-31 Rs522.15 Million
≈ $5.65 Million
Rs120.85 Million
≈ $1.31 Million
0.231x +22.22%
2020-03-31 Rs406.15 Million
≈ $4.39 Million
Rs76.91 Million
≈ $831.77K
0.189x -27.23%
2019-03-31 Rs291.17 Million
≈ $3.15 Million
Rs75.77 Million
≈ $819.45K
0.260x +24.73%
2018-03-31 Rs206.99 Million
≈ $2.24 Million
Rs43.18 Million
≈ $467.01K
0.209x -56.32%
2017-03-31 Rs192.03 Million
≈ $2.08 Million
Rs91.72 Million
≈ $991.96K
0.478x +27.00%
2016-03-31 Rs173.56 Million
≈ $1.88 Million
Rs65.27 Million
≈ $705.91K
0.376x --

About Par Drugs And Chemicals Limited

NSE:PAR India Drug Manufacturers - Specialty & Generic
Market Cap
$18.18 Million
Rs1.68 Billion INR
Market Cap Rank
#25510 Global
#1407 in India
Share Price
Rs136.60
Change (1 day)
+2.29%
52-Week Range
Rs78.58 - Rs168.25
All Time High
Rs348.45
About

Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, m… Read more